Loading…
Loading…
LMRI (Lumexa Imaging Holdings, Inc. Common Stock) is a recent IPO.
It began trading on December 11, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates. The affected sections are flagged individually so you can tell limited history from missing data.
Lumexa Imaging (NASDAQ: LMRI - Get Free Report) and DocGo (NASDAQ: DCGO - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Institutional and Insider Ownership 56.4% of DocGo shares
Shares of Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI - Get Free Report) have earned an average recommendation of "Buy" from the five analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have given a strong buy recommendation
Lumexa (LMRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BlackRock Inc. bought a new position in shares of Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,398,112 shares of the company's stock, valued at approximately $15,771,000. BlackRock Inc. owned approximately 1.46%
RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, held in Boston, including a fireside chat at 3:00 PM ET and one-on-one meetings with Caitlin Zulla and Tony Martin on September 9, 2026.
The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript